

A guide to ICD-10-CM coding for patients who are prescribed PRALUENT  
for an indication approved by the US Food and Drug Administration

# PRALUENT ICD-10-CM pocket guide

The coding information discussed in this document is provided for informational purposes only, is subject to change, and should not be construed as legal advice. The codes listed herein may not apply to all patients or to all health plans; providers should exercise independent clinical judgment when selecting codes and submitting claims to accurately reflect the services and products furnished to a specific patient.

## Indications and Usage

PRALUENT is indicated:

- to reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease.
- as an adjunct to diet, alone or in combination with other lipid-lowering therapies (e.g., statins, ezetimibe), for the treatment of adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia) to reduce low-density lipoprotein cholesterol (LDL-C).

## Important Safety Information

PRALUENT is contraindicated in patients with a history of a serious hypersensitivity reaction to PRALUENT, including hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization.

Hypersensitivity reactions (e.g., pruritus, rash, urticaria), including some serious events (e.g., hypersensitivity vasculitis, angioedema, and hypersensitivity reactions requiring hospitalization), have been reported with PRALUENT treatment. If signs or symptoms of serious allergic reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve.

ICD-10-CM=International Classification of Diseases, Tenth Revision, Clinical Modification.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.

  
**Praluent**<sup>®</sup>  
(alirocumab) Injection 75mg/mL  
150mg/mL

## Primary and secondary ICD-10-CM codes

Section 1	<b>Disorders of lipoprotein metabolism and other lipidemias</b> .....	3
	<b>Transient cerebral ischemic attacks and related syndromes</b> .....	3
	<b>Ischemic heart diseases</b> .....	3
	Angina pectoris .....	3
	Acute myocardial infarction .....	3
	Subsequent ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction .....	3
	Certain current complications following ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction (within the 28-day period) .....	3
	Other acute ischemic heart diseases .....	4
	Chronic ischemic heart disease .....	4
Section 2	<b>Cerebrovascular diseases</b> .....	5
	Cerebral infarction .....	5
	Occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction .....	7
	Occlusion and stenosis of cerebral arteries, not resulting in cerebral infarction .....	8
	Other cerebrovascular diseases .....	8
Section 3	<b>Diseases of arteries, arterioles, and capillaries</b> .....	9
	Atherosclerosis .....	9
	Other peripheral vascular diseases .....	15
Section 4	<b>Family history of other specific disorders</b> .....	16
	<b>Presence of cardiac and vascular implants and grafts</b> .....	16
	<b>Other postprocedural states</b> .....	16

Please use as many secondary codes as needed to appropriately describe your patient's condition.

## Need additional support?



Visit  
PRALUENT.com

OR



Call  
1-844-PRALUENT (1-844-772-5836),  
Monday-Friday, 8 AM-8 PM Eastern time

Brought to you by Regeneron Pharmaceuticals, Inc.

Please see Important Safety Information throughout and [click here](#) for full Prescribing Information.



### E78: Disorders of lipoprotein metabolism and other lipidemias

<b>E78.0</b>	Pure hypercholesterolemia
<b>E78.00</b>	Pure hypercholesterolemia, unspecified
<b>E78.01</b>	Familial hypercholesterolemia
<b>E78.2</b>	Mixed hyperlipidemia
<b>E78.4</b>	Other hyperlipidemia
<b>E78.5</b>	Hyperlipidemia, unspecified

### G45: Transient cerebral ischemic attacks and related syndromes

<b>G45.0</b>	Vertebro-basilar artery syndrome
<b>G45.1</b>	Carotid artery syndrome (hemispheric)
<b>G45.2</b>	Multiple and bilateral precerebral artery syndromes
<b>G45.8</b>	Other transient cerebral ischemic attacks and related syndromes
<b>G45.9</b>	Transient cerebral ischemic attack, unspecified

### Ischemic heart diseases

#### **I20: Angina pectoris**

<b>I20.0</b>	Unstable angina
<b>I20.1</b>	Angina pectoris with documented spasm
<b>I20.8</b>	Other forms of angina pectoris
<b>I20.9</b>	Angina pectoris, unspecified

#### **I21: Acute myocardial infarction**

<b>I21.0</b>	ST elevation (STEMI) myocardial infarction of anterior wall
<b>I21.01</b>	ST elevation (STEMI) myocardial infarction involving left main coronary artery
<b>I21.02</b>	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery
<b>I21.09</b>	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall
<b>I21.1</b>	ST elevation (STEMI) myocardial infarction of inferior wall
<b>I21.11</b>	ST elevation (STEMI) myocardial infarction involving right coronary artery
<b>I21.19</b>	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall
<b>I21.2</b>	ST elevation (STEMI) myocardial infarction of other sites
<b>I21.21</b>	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery
<b>I21.29</b>	ST elevation (STEMI) myocardial infarction involving other sites
<b>I21.3</b>	ST elevation (STEMI) myocardial infarction of unspecified site
<b>I21.4</b>	Non-ST elevation (NSTEMI) myocardial infarction
<b>I21.9</b>	Acute myocardial infarction, unspecified
<b>I21.A</b>	Other type of myocardial infarction
<b>I21.A9</b>	Other myocardial infarction type

#### **I22: Subsequent ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction**

<b>I22.0</b>	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall
<b>I22.1</b>	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall
<b>I22.2</b>	Subsequent non-ST elevation (NSTEMI) myocardial infarction
<b>I22.8</b>	Subsequent ST elevation (STEMI) myocardial infarction of other sites
<b>I22.9</b>	Subsequent ST elevation (STEMI) myocardial infarction of unspecified sites

#### **I23: Certain current complications following ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction (within the 28-day period)**

<b>I23.7</b>	Postinfarction angina
<b>I23.8</b>	Other current complications following acute myocardial infarction

### Important Safety Information (cont'd)

The most commonly occurring adverse reactions in clinical trials in primary hyperlipidemia (including heterozygous familial hypercholesterolemia (HeFH)) ( $\geq 5\%$  of patients treated with PRALUENT and occurring more frequently than with placebo) are nasopharyngitis, injection site reactions, and influenza.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.

  
**Praluent**<sup>®</sup>  
(alirocumab) Injection 75mg/mL  
150mg/mL

**Ischemic heart diseases (cont'd)****I24: Other acute ischemic heart diseases****I24.8** Other forms of acute ischemic heart disease**I24.9** Acute ischemic heart disease, unspecified**I25: Chronic ischemic heart disease****I25.10** Atherosclerotic heart disease of native coronary artery without angina pectoris**I25.110** Atherosclerotic heart disease of native coronary artery with unstable angina pectoris**I25.111** Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm**I25.118** Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris**I25.119** Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris**I25.2** Old myocardial infarction**I25.700** Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris**I25.701** Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm**I25.708** Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris**I25.709** Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris**I25.710** Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris**I25.711** Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm**I25.718** Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris**I25.719** Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris**I25.720** Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris**I25.721** Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm**I25.728** Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris**I25.729** Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris**I25.730** Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris**I25.731** Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm**I25.738** Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris**I25.739** Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris**I25.750** Atherosclerosis of native coronary artery of transplanted heart with unstable angina**I25.751** Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm**I25.758** Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris**I25.759** Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris**I25.760** Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina**I25.761** Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm**I25.768** Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris**I25.769** Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris**I25.790** Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris**I25.791** Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm**I25.798** Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris**I25.799** Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris**I25.810** Atherosclerosis of coronary artery bypass graft(s) without angina pectoris**I25.811** Atherosclerosis of native coronary artery of transplanted heart without angina pectoris**I25.812** Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris**I25.83** Coronary atherosclerosis due to lipid rich plaque**I25.84** Coronary atherosclerosis due to calcified coronary artery lesion**Important Safety Information (cont'd)**

The most commonly occurring adverse reactions in the cardiovascular outcomes trial (>5% of patients treated with PRALUENT and occurring more frequently than placebo) were non-cardiac chest pain, nasopharyngitis, and myalgia.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.



**Praluent**<sup>®</sup>  
(alirocumab) Injection 75mg/mL  
150mg/mL

## Cerebrovascular diseases

### **I63: Cerebral infarction**

<b>I63.0</b>	Cerebral infarction due to thrombosis of precerebral arteries
<b>I63.00</b>	Cerebral infarction due to thrombosis of unspecified precerebral artery
<b>I63.01</b>	Cerebral infarction due to thrombosis of vertebral artery
<b>I63.011</b>	Cerebral infarction due to thrombosis of right vertebral artery
<b>I63.012</b>	Cerebral infarction due to thrombosis of left vertebral artery
<b>I63.013</b>	Cerebral infarction due to thrombosis of bilateral vertebral arteries
<b>I63.019</b>	Cerebral infarction due to thrombosis of unspecified vertebral artery
<b>I63.02</b>	Cerebral infarction due to thrombosis of basilar artery
<b>I63.03</b>	Cerebral infarction due to thrombosis of carotid artery
<b>I63.031</b>	Cerebral infarction due to thrombosis of right carotid artery
<b>I63.032</b>	Cerebral infarction due to thrombosis of left carotid artery
<b>I63.033</b>	Cerebral infarction due to thrombosis of bilateral carotid arteries
<b>I63.039</b>	Cerebral infarction due to thrombosis of unspecified carotid artery
<b>I63.09</b>	Cerebral infarction due to thrombosis of other precerebral artery
<b>I63.10</b>	Cerebral infarction due to embolism of unspecified precerebral artery
<b>I63.111</b>	Cerebral infarction due to embolism of right vertebral artery
<b>I63.112</b>	Cerebral infarction due to embolism of left vertebral artery
<b>I63.113</b>	Cerebral infarction due to embolism of bilateral vertebral arteries
<b>I63.119</b>	Cerebral infarction due to embolism of unspecified vertebral artery
<b>I63.12</b>	Cerebral infarction due to embolism of basilar artery
<b>I63.131</b>	Cerebral infarction due to embolism of right carotid artery
<b>I63.132</b>	Cerebral infarction due to embolism of left carotid artery
<b>I63.133</b>	Cerebral infarction due to embolism of bilateral carotid arteries
<b>I63.139</b>	Cerebral infarction due to embolism of unspecified carotid artery
<b>I63.19</b>	Cerebral infarction due to embolism of other precerebral artery
<b>I63.2</b>	Cerebral infarction due to unspecified occlusion or stenosis of precerebral arteries
<b>I63.20</b>	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries
<b>I63.21</b>	Cerebral infarction due to unspecified occlusion or stenosis of vertebral arteries
<b>I63.211</b>	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery
<b>I63.212</b>	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery
<b>I63.213</b>	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries
<b>I63.219</b>	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral arteries
<b>I63.22</b>	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery
<b>I63.23</b>	Cerebral infarction due to unspecified occlusion or stenosis of carotid arteries
<b>I63.231</b>	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries
<b>I63.232</b>	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries
<b>I63.233</b>	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries
<b>I63.239</b>	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid arteries
<b>I63.29</b>	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries

### **Important Safety Information (cont'd)**

In the primary hyperlipidemia (including HeFH) clinical trials, local injection site reactions including erythema/redness, itching, swelling, and pain/tenderness were reported more frequently in patients treated with PRALUENT 75 mg and/or 150 mg every 2 weeks (7.2% versus 5.1% for PRALUENT and placebo, respectively). Few patients discontinued treatment because of these reactions (0.2% versus 0.4% for PRALUENT and placebo, respectively), but patients receiving PRALUENT had a greater number of injection site reactions, had more reports of associated symptoms, and had reactions of longer average duration than patients receiving placebo.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.

**Praluent**<sup>®</sup>  
(alirocumab) Injection 75mg/mL  
150mg/mL

**I63: Cerebral infarction (cont'd)**

<b>I63.3</b>	Cerebral infarction due to thrombosis of cerebral arteries
<b>I63.30</b>	Cerebral infarction due to thrombosis of unspecified cerebral artery
<b>I63.31</b>	Cerebral infarction due to thrombosis of middle cerebral artery
<b>I63.311</b>	Cerebral infarction due to thrombosis of right middle cerebral artery
<b>I63.312</b>	Cerebral infarction due to thrombosis of left middle cerebral artery
<b>I63.313</b>	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries
<b>I63.319</b>	Cerebral infarction due to thrombosis of unspecified middle cerebral artery
<b>I63.32</b>	Cerebral infarction due to thrombosis of anterior cerebral artery
<b>I63.321</b>	Cerebral infarction due to thrombosis of right anterior cerebral artery
<b>I63.322</b>	Cerebral infarction due to thrombosis of left anterior cerebral artery
<b>I63.323</b>	Cerebral infarction due to thrombosis of bilateral anterior arteries
<b>I63.329</b>	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery
<b>I63.33</b>	Cerebral infarction due to thrombosis of posterior cerebral artery
<b>I63.331</b>	Cerebral infarction due to thrombosis of right posterior cerebral artery
<b>I63.332</b>	Cerebral infarction due to thrombosis of left posterior cerebral artery
<b>I63.333</b>	Cerebral infarction due to thrombosis of bilateral posterior cerebral arteries
<b>I63.339</b>	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery
<b>I63.34</b>	Cerebral infarction due to thrombosis of cerebellar artery
<b>I63.341</b>	Cerebral infarction due to thrombosis of right cerebellar artery
<b>I63.342</b>	Cerebral infarction due to thrombosis of left cerebellar artery
<b>I63.343</b>	Cerebral infarction due to thrombosis of bilateral cerebellar arteries
<b>I63.349</b>	Cerebral infarction due to thrombosis of unspecified cerebellar artery
<b>I63.39</b>	Cerebral infarction due to thrombosis of other cerebral artery
<b>I63.40</b>	Cerebral infarction due to embolism of unspecified cerebral artery
<b>I63.411</b>	Cerebral infarction due to embolism of right middle cerebral artery
<b>I63.412</b>	Cerebral infarction due to embolism of left middle cerebral artery
<b>I63.413</b>	Cerebral infarction due to embolism of bilateral middle cerebral arteries
<b>I63.419</b>	Cerebral infarction due to embolism of unspecified middle cerebral artery
<b>I63.421</b>	Cerebral infarction due to embolism of right anterior cerebral artery
<b>I63.422</b>	Cerebral infarction due to embolism of left anterior cerebral artery
<b>I63.423</b>	Cerebral infarction due to embolism of bilateral anterior cerebral arteries
<b>I63.429</b>	Cerebral infarction due to embolism of unspecified anterior cerebral artery
<b>I63.431</b>	Cerebral infarction due to embolism of right posterior cerebral artery
<b>I63.432</b>	Cerebral infarction due to embolism of left posterior cerebral artery
<b>I63.433</b>	Cerebral infarction due to embolism of bilateral posterior cerebral arteries
<b>I63.439</b>	Cerebral infarction due to embolism of unspecified posterior cerebral artery
<b>I63.441</b>	Cerebral infarction due to embolism of right cerebellar artery
<b>I63.442</b>	Cerebral infarction due to embolism of left cerebellar artery
<b>I63.443</b>	Cerebral infarction due to embolism of bilateral cerebellar arteries
<b>I63.449</b>	Cerebral infarction due to embolism of unspecified cerebellar artery
<b>I63.49</b>	Cerebral infarction due to embolism of other cerebral artery

**Important Safety Information (cont'd)**

The once-monthly (Q4W) 300mg dosing regimen had a higher rate of local injection site reactions as compared to PRALUENT 75mg Q2W or placebo (16.6%, 9.6%, and 7.9%, respectively) in a trial in which all patients received an injection of drug or placebo every 2 weeks to maintain the blind. The discontinuation rate due to injection site reactions was 0.7% in the 300 mg Q4W arm and 0% in the other 2 arms.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.

**Praluent**<sup>®</sup>  
(alirocumab) Injection 75mg/mL  
150mg/mL



**I63: Cerebral infarction (cont'd)**

<b>I63.50</b>	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery
<b>I63.511</b>	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery
<b>I63.512</b>	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery
<b>I63.513</b>	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries
<b>I63.519</b>	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery
<b>I63.52</b>	Cerebral infarction due to unspecified occlusion or stenosis of anterior cerebral artery
<b>I63.521</b>	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery
<b>I63.522</b>	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery
<b>I63.523</b>	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries
<b>I63.529</b>	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery
<b>I63.53</b>	Cerebral infarction due to unspecified occlusion or stenosis of posterior cerebral artery
<b>I63.531</b>	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery
<b>I63.532</b>	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery
<b>I63.533</b>	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries
<b>I63.539</b>	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery
<b>I63.54</b>	Cerebral infarction due to unspecified occlusion or stenosis of cerebellar artery
<b>I63.541</b>	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery
<b>I63.542</b>	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery
<b>I63.543</b>	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries
<b>I63.549</b>	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery
<b>I63.59</b>	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery
<b>I63.6</b>	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic
<b>I63.8</b>	Other cerebral infarction
<b>I63.9</b>	Cerebral infarction, unspecified

**I65: Occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction**

<b>I65.0</b>	Occlusion and stenosis of vertebral artery
<b>I65.01</b>	Occlusion and stenosis of right vertebral artery
<b>I65.02</b>	Occlusion and stenosis of left vertebral artery
<b>I65.03</b>	Occlusion and stenosis of bilateral vertebral arteries
<b>I65.09</b>	Occlusion and stenosis of unspecified vertebral artery
<b>I65.1</b>	Occlusion and stenosis of basilar artery
<b>I65.2</b>	Occlusion and stenosis of carotid artery
<b>I65.21</b>	Occlusion and stenosis of right carotid artery
<b>I65.22</b>	Occlusion and stenosis of left carotid artery
<b>I65.23</b>	Occlusion and stenosis of bilateral carotid arteries
<b>I65.29</b>	Occlusion and stenosis of unspecified carotid artery
<b>I65.8</b>	Occlusion and stenosis of other precerebral arteries
<b>I65.9</b>	Occlusion and stenosis of unspecified precerebral artery

**Important Safety Information (cont'd)**

In a cardiovascular outcomes trial, local injection site reactions were reported in 3.8% of patients treated with PRALUENT versus 2.1% patients treated with placebo, and led to permanent discontinuation in 0.3% of patients versus <0.1% of patients, respectively.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.

**Praluent**<sup>®</sup>  
(alirocumab) Injection 75mg/mL  
150mg/mL

**I66: Occlusion and stenosis of cerebral arteries, not resulting in cerebral infarction**

<b>I66.0</b>	Occlusion and stenosis of middle cerebral artery
<b>I66.01</b>	Occlusion and stenosis of right middle cerebral artery
<b>I66.02</b>	Occlusion and stenosis of left middle cerebral artery
<b>I66.03</b>	Occlusion and stenosis of bilateral middle cerebral arteries
<b>I66.09</b>	Occlusion and stenosis of unspecified middle cerebral artery
<b>I66.1</b>	Occlusion and stenosis of anterior cerebral artery
<b>I66.11</b>	Occlusion and stenosis of right anterior cerebral artery
<b>I66.12</b>	Occlusion and stenosis of left anterior cerebral artery
<b>I66.13</b>	Occlusion and stenosis of bilateral anterior cerebral arteries
<b>I66.19</b>	Occlusion and stenosis of unspecified anterior cerebral artery
<b>I66.2</b>	Occlusion and stenosis of posterior cerebral artery
<b>I66.21</b>	Occlusion and stenosis of right posterior cerebral artery
<b>I66.22</b>	Occlusion and stenosis of left posterior cerebral artery
<b>I66.23</b>	Occlusion and stenosis of bilateral posterior cerebral arteries
<b>I66.29</b>	Occlusion and stenosis of unspecified posterior cerebral artery
<b>I66.3</b>	Occlusion and stenosis of cerebellar arteries
<b>I66.8</b>	Occlusion and stenosis of other cerebral arteries
<b>I66.9</b>	Occlusion and stenosis of unspecified cerebral artery

**I67: Other cerebrovascular diseases**

<b>I67.2</b>	Cerebral atherosclerosis
<b>I67.81</b>	Acute cerebrovascular insufficiency
<b>I67.82</b>	Cerebral ischemia

**Important Safety Information (cont'd)**

In the primary hyperlipidemia trials, liver-related disorders (primarily related to abnormalities in liver enzymes) were reported in 2.5% of patients treated with PRALUENT and 1.8% of patients treated with placebo, leading to treatment discontinuation in 0.4% and 0.2% of patients, respectively. Increases in serum transaminases to greater than 3 times the upper limit of normal occurred in 1.7% of patients treated with PRALUENT and 1.4% of patients treated with placebo.

In the primary hyperlipidemia trials, the most common adverse reactions leading to treatment discontinuation in patients treated with PRALUENT were allergic reactions (0.6% versus 0.2% for PRALUENT and placebo, respectively) and elevated liver enzymes (0.3% versus <0.1%).

PRALUENT is a human monoclonal antibody. As with all therapeutic proteins, there is a potential for immunogenicity with PRALUENT.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.

**Praluent**<sup>®</sup>  
(alirocumab) Injection 75mg/mL  
150mg/mL



## Diseases of arteries, arterioles, and capillaries

### I70: Atherosclerosis

<b>I70.0</b>	Atherosclerosis of aorta
<b>I70.1</b>	Atherosclerosis of renal artery
<b>I70.2</b>	Atherosclerosis of native arteries of the extremities
<b>I70.20</b>	Unspecified atherosclerosis of native arteries of extremities
<b>I70.201</b>	Unspecified atherosclerosis of native arteries of extremities, right leg
<b>I70.202</b>	Unspecified atherosclerosis of native arteries of extremities, left leg
<b>I70.203</b>	Unspecified atherosclerosis of native arteries of extremities, bilateral legs
<b>I70.208</b>	Unspecified atherosclerosis of native arteries of extremities, other extremity
<b>I70.209</b>	Unspecified atherosclerosis of native arteries of extremities, unspecified extremity
<b>I70.21</b>	Atherosclerosis of native arteries of extremities with intermittent claudication
<b>I70.211</b>	Atherosclerosis of native arteries of extremities with intermittent claudication, right leg
<b>I70.212</b>	Atherosclerosis of native arteries of extremities with intermittent claudication, left leg
<b>I70.213</b>	Atherosclerosis of native arteries of extremities with intermittent claudication, bilateral legs
<b>I70.218</b>	Atherosclerosis of native arteries of extremities with intermittent claudication, other extremity
<b>I70.219</b>	Atherosclerosis of native arteries of extremities with intermittent claudication, unspecified extremity
<b>I70.22</b>	Atherosclerosis of native arteries of extremities with rest pain
<b>I70.221</b>	Atherosclerosis of native arteries of extremities with rest pain, right leg
<b>I70.222</b>	Atherosclerosis of native arteries of extremities with rest pain, left leg
<b>I70.223</b>	Atherosclerosis of native arteries of extremities with rest pain, bilateral legs
<b>I70.228</b>	Atherosclerosis of native arteries of extremities with rest pain, other extremity
<b>I70.229</b>	Atherosclerosis of native arteries of extremities with rest pain, unspecified extremity
<b>I70.23</b>	Atherosclerosis of native arteries of right leg with ulceration
<b>I70.231</b>	Atherosclerosis of native arteries of right leg with ulceration of thigh
<b>I70.232</b>	Atherosclerosis of native arteries of right leg with ulceration of calf
<b>I70.233</b>	Atherosclerosis of native arteries of right leg with ulceration of ankle
<b>I70.234</b>	Atherosclerosis of native arteries of right leg with ulceration of heel and midfoot
<b>I70.235</b>	Atherosclerosis of native arteries of right leg with ulceration of other part of foot
<b>I70.238</b>	Atherosclerosis of native arteries of right leg with ulceration of other part of lower right leg
<b>I70.239</b>	Atherosclerosis of native arteries of right leg with ulceration of unspecified site
<b>I70.24</b>	Atherosclerosis of native arteries of left leg with ulceration
<b>I70.241</b>	Atherosclerosis of native arteries of left leg with ulceration of thigh
<b>I70.242</b>	Atherosclerosis of native arteries of left leg with ulceration of calf
<b>I70.243</b>	Atherosclerosis of native arteries of left leg with ulceration of ankle
<b>I70.244</b>	Atherosclerosis of native arteries of left leg with ulceration of heel and midfoot
<b>I70.245</b>	Atherosclerosis of native arteries of left leg with ulceration of other part of foot
<b>I70.248</b>	Atherosclerosis of native arteries of left leg with ulceration of other part of lower left leg
<b>I70.249</b>	Atherosclerosis of native arteries of left leg with ulceration of unspecified site
<b>I70.25</b>	Atherosclerosis of native arteries of other extremities with ulceration

### Important Safety Information

PRALUENT is contraindicated in patients with a history of a serious hypersensitivity reaction to PRALUENT, including hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization.

Hypersensitivity reactions (e.g., pruritus, rash, urticaria), including some serious events (e.g., hypersensitivity vasculitis, angioedema, and hypersensitivity reactions requiring hospitalization), have been reported with PRALUENT treatment.

If signs or symptoms of serious allergic reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.

**Praluent**<sup>®</sup>  
(alirocumab) Injection 75mg/mL  
150mg/mL

**I70: Atherosclerosis (cont'd)**

<b>I70.26</b>	Atherosclerosis of native arteries of extremities with gangrene
<b>I70.261</b>	Atherosclerosis of native arteries of extremities with gangrene, right leg
<b>I70.262</b>	Atherosclerosis of native arteries of extremities with gangrene, left leg
<b>I70.263</b>	Atherosclerosis of native arteries of extremities with gangrene, bilateral legs
<b>I70.268</b>	Atherosclerosis of native arteries of extremities with gangrene, other extremity
<b>I70.269</b>	Atherosclerosis of native arteries of extremities with gangrene, unspecified extremity
<b>I70.29</b>	Other atherosclerosis of native arteries of extremities
<b>I70.291</b>	Other atherosclerosis of native arteries of extremities, right leg
<b>I70.292</b>	Other atherosclerosis of native arteries of extremities, left leg
<b>I70.293</b>	Other atherosclerosis of native arteries of extremities, bilateral legs
<b>I70.298</b>	Other atherosclerosis of native arteries of extremities, other extremity
<b>I70.299</b>	Other atherosclerosis of native arteries of extremities, unspecified extremity
<b>I70.3</b>	Atherosclerosis of unspecified type of bypass graft(s) of the extremities
<b>I70.30</b>	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities
<b>I70.301</b>	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, right leg
<b>I70.302</b>	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, left leg
<b>I70.303</b>	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, bilateral legs
<b>I70.308</b>	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, other extremity
<b>I70.309</b>	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, unspecified extremity
<b>I70.31</b>	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication
<b>I70.311</b>	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, right leg
<b>I70.312</b>	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, left leg
<b>I70.313</b>	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, bilateral legs
<b>I70.318</b>	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, other extremity
<b>I70.319</b>	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, unspecified extremity
<b>I70.32</b>	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain
<b>I70.321</b>	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, right leg
<b>I70.322</b>	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, left leg
<b>I70.323</b>	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, bilateral legs
<b>I70.328</b>	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, other extremity
<b>I70.329</b>	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, unspecified extremity
<b>I70.331</b>	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of thigh
<b>I70.332</b>	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of calf
<b>I70.333</b>	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of ankle
<b>I70.334</b>	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of heel and midfoot
<b>I70.335</b>	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of other part of foot
<b>I70.338</b>	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of other part of lower leg
<b>I70.339</b>	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of unspecified site
<b>I70.34</b>	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration
<b>I70.341</b>	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of thigh
<b>I70.342</b>	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of calf
<b>I70.343</b>	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of ankle
<b>I70.344</b>	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of heel and midfoot
<b>I70.345</b>	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of other part of foot
<b>I70.348</b>	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of other part of lower leg
<b>I70.349</b>	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of unspecified site

**Important Safety Information (cont'd)**

The most commonly occurring adverse reactions in clinical trials in primary hyperlipidemia (including heterozygous familial hypercholesterolemia (HeFH)) ( $\geq 5\%$  of patients treated with PRALUENT and occurring more frequently than with placebo) are nasopharyngitis, injection site reactions, and influenza.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.

**Praluent**<sup>®</sup>  
(alirocumab) Injection 75mg/mL  
150mg/mL

**I70: Atherosclerosis (cont'd)**

<b>I70.35</b>	Atherosclerosis, unspecified type of bypass graft(s) of other extremity with ulceration
<b>I70.36</b>	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene
<b>I70.361</b>	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, right leg
<b>I70.362</b>	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, left leg
<b>I70.363</b>	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, bilateral legs
<b>I70.368</b>	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, other extremity
<b>I70.369</b>	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, unspecified extremity
<b>I70.39</b>	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities
<b>I70.391</b>	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, right leg
<b>I70.392</b>	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, left leg
<b>I70.393</b>	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, bilateral legs
<b>I70.398</b>	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, other extremity
<b>I70.399</b>	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, unspecified extremity
<b>I70.4</b>	Atherosclerosis of autologous vein bypass graft(s) of the extremities
<b>I70.40</b>	Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities
<b>I70.401</b>	Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, right leg
<b>I70.402</b>	Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, left leg
<b>I70.403</b>	Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, bilateral legs
<b>I70.408</b>	Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, other extremity
<b>I70.409</b>	Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, unspecified extremity
<b>I70.41</b>	Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication
<b>I70.411</b>	Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, right leg
<b>I70.412</b>	Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, left leg
<b>I70.413</b>	Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, bilateral legs
<b>I70.418</b>	Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, other extremity
<b>I70.419</b>	Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, unspecified extremity
<b>I70.42</b>	Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain
<b>I70.421</b>	Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, right leg
<b>I70.422</b>	Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, left leg
<b>I70.423</b>	Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, bilateral legs
<b>I70.428</b>	Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, other extremity
<b>I70.429</b>	Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, unspecified extremity
<b>I70.43</b>	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration
<b>I70.431</b>	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of thigh
<b>I70.432</b>	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of calf
<b>I70.433</b>	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of ankle
<b>I70.434</b>	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of heel and midfoot
<b>I70.435</b>	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of other part of foot
<b>I70.438</b>	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of other part of lower leg
<b>I70.439</b>	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of unspecified site
<b>I70.44</b>	Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration
<b>I70.441</b>	Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of thigh
<b>I70.442</b>	Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of calf
<b>I70.443</b>	Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of ankle
<b>I70.444</b>	Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of heel and midfoot
<b>I70.445</b>	Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of other part of foot

**Important Safety Information (cont'd)**

The most commonly occurring adverse reactions in the cardiovascular outcomes trial (>5% of patients treated with PRALUENT and occurring more frequently than placebo) were non-cardiac chest pain, nasopharyngitis, and myalgia.

Please see additional Important Safety Information throughout and [click here for full Prescribing Information](#).



**Praluent**<sup>®</sup>  
(alirocumab) Injection 75mg/mL  
150mg/mL

**I70: Atherosclerosis (cont'd)**

- I70.448** Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of other part of lower leg
- I70.449** Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of unspecified site
- I70.45** Atherosclerosis of autologous vein bypass graft(s) of other extremity with ulceration
- I70.46** Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene
- I70.461** Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, right leg
- I70.462** Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, left leg
- I70.463** Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, bilateral legs
- I70.468** Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, other extremity
- I70.469** Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, unspecified extremity
- I70.491** Other atherosclerosis of autologous vein bypass graft(s) of the extremities, right leg
- I70.492** Other atherosclerosis of autologous vein bypass graft(s) of the extremities, left leg
- I70.493** Other atherosclerosis of autologous vein bypass graft(s) of the extremities, bilateral legs
- I70.498** Other atherosclerosis of autologous vein bypass graft(s) of the extremities, other extremity
- I70.499** Other atherosclerosis of autologous vein bypass graft(s) of the extremities, unspecified extremity
- I70.5** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities
- I70.50** Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities
- I70.501** Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, right leg
- I70.502** Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, left leg
- I70.503** Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, bilateral legs
- I70.508** Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, other extremity
- I70.509** Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, unspecified extremity
- I70.51** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities intermittent claudication
- I70.511** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, right leg
- I70.512** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, left leg
- I70.513** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, bilateral legs
- I70.518** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, other extremity
- I70.519** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, unspecified extremity
- I70.52** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain
- I70.521** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, right leg
- I70.522** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, left leg
- I70.523** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, bilateral legs
- I70.528** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, other extremity
- I70.529** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, unspecified extremity
- I70.53** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration
- I70.531** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of thigh
- I70.532** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of calf
- I70.533** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of ankle
- I70.534** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of heel and midfoot
- I70.535** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of other part of foot
- I70.538** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of other part of lower leg
- I70.539** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of unspecified site
- I70.54** Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration

**Important Safety Information (cont'd)**

In the primary hyperlipidemia (including HeFH) clinical trials, local injection site reactions including erythema/redness, itching, swelling, and pain/tenderness were reported more frequently in patients treated with PRALUENT 75 mg and/or 150 mg every 2 weeks (7.2% versus 5.1% for PRALUENT and placebo, respectively). Few patients discontinued treatment because of these reactions (0.2% versus 0.4% for PRALUENT and placebo, respectively), but patients receiving PRALUENT had a greater number of injection site reactions, had more reports of associated symptoms, and had reactions of longer average duration than patients receiving placebo.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.

**Praluent**<sup>®</sup>  
(alirocumab) Injection 75mg/mL  
150mg/mL



**I70: Atherosclerosis (cont'd)**

- I70.541** Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of thigh
- I70.542** Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of calf
- I70.543** Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of ankle
- I70.544** Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of heel and midfoot
- I70.545** Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of other part of foot
- I70.548** Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of other part of lower leg
- I70.549** Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of unspecified site
- I70.55** Atherosclerosis of nonautologous biological bypass graft(s) of other extremity with ulceration
- I70.56** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene
- I70.561** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, right leg
- I70.562** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, left leg
- I70.563** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, bilateral legs
- I70.568** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, other extremity
- I70.569** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, unspecified extremity
- I70.59** Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities
- I70.591** Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, right leg
- I70.592** Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, left leg
- I70.593** Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, bilateral legs
- I70.598** Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, other extremity
- I70.599** Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, unspecified extremity
- I70.6** Atherosclerosis of nonbiological bypass graft(s) of the extremities
- I70.60** Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities
- I70.601** Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, right leg
- I70.602** Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, left leg
- I70.603** Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, bilateral legs
- I70.608** Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, other extremity
- I70.609** Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, unspecified extremity
- I70.61** Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication
- I70.611** Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, right leg
- I70.612** Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, left leg
- I70.613** Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, bilateral legs
- I70.618** Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, other extremity
- I70.619** Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, unspecified extremity
- I70.62** Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain
- I70.621** Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, right leg
- I70.622** Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, left leg
- I70.623** Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, bilateral legs
- I70.628** Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, other extremity
- I70.629** Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, unspecified extremity
- I70.63** Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration
- I70.631** Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of thigh
- I70.632** Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of calf
- I70.633** Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of ankle

**Important Safety Information (cont'd)**

The once-monthly (Q4W) 300mg dosing regimen had a higher rate of local injection site reactions as compared to PRALUENT 75mg Q2W or placebo (16.6%, 9.6%, and 7.9%, respectively) in a trial in which all patients received an injection of drug or placebo every 2 weeks to maintain the blind. The discontinuation rate due to injection site reactions was 0.7% in the 300 mg Q4W arm and 0% in the other 2 arms.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.



**Praluent**<sup>®</sup>  
(alirocumab) Injection 75mg/mL  
150mg/mL

**I70: Atherosclerosis (cont'd)**

- I70.634 Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of heel and midfoot
- I70.635 Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of other part of foot
- I70.638 Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of other part of lower leg
- I70.639 Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of unspecified site
- I70.64 Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration
- I70.641 Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of thigh
- I70.642 Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of calf
- I70.643 Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of ankle
- I70.644 Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of heel and midfoot
- I70.645 Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of other part of foot
- I70.648 Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of other part of lower leg
- I70.649 Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of unspecified site
- I70.65 Atherosclerosis of nonbiological bypass graft(s) of other extremity with ulceration
- I70.66 Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene
- I70.661 Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, right leg
- I70.662 Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, left leg
- I70.663 Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, bilateral legs
- I70.668 Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, other extremity
- I70.669 Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, unspecified extremity
- I70.69 Other atherosclerosis of nonbiological bypass graft(s) of the extremities
- I70.691 Other atherosclerosis of nonbiological bypass graft(s) of the extremities, right leg
- I70.692 Other atherosclerosis of nonbiological bypass graft(s) of the extremities, left leg
- I70.693 Other atherosclerosis of nonbiological bypass graft(s) of the extremities, bilateral legs
- I70.698 Other atherosclerosis of nonbiological bypass graft(s) of the extremities, other extremity
- I70.699 Other atherosclerosis of nonbiological bypass graft(s) of the extremities, unspecified extremity
- I70.7 Atherosclerosis of other type of bypass graft(s) of the extremities
- I70.70 Unspecified atherosclerosis of other type of bypass graft(s) of the extremities
- I70.701 Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, right leg
- I70.702 Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, left leg
- I70.703 Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, bilateral legs
- I70.708 Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, other extremity
- I70.709 Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, unspecified extremity
- I70.71 Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication
- I70.711 Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, right leg
- I70.712 Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, left leg
- I70.713 Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, bilateral legs
- I70.718 Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, other extremity
- I70.719 Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, unspecified extremity
- I70.72 Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain
- I70.721 Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, right leg
- I70.722 Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, left leg
- I70.723 Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, bilateral legs

**Important Safety Information (cont'd)**

In a cardiovascular outcomes trial, local injection site reactions were reported in 3.8% of patients treated with PRALUENT versus 2.1% patients treated with placebo, and led to permanent discontinuation in 0.3% of patients versus <0.1% of patients, respectively.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.

**Praluent**<sup>®</sup>  
(alirocumab) Injection 75mg/mL  
150mg/mL



**I70: Atherosclerosis (cont'd)**

<b>I70.728</b>	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, other extremity
<b>I70.729</b>	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, unspecified extremity
<b>I70.73</b>	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration
<b>I70.731</b>	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of thigh
<b>I70.732</b>	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of calf
<b>I70.733</b>	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of ankle
<b>I70.734</b>	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of heel and midfoot
<b>I70.735</b>	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of other part of foot
<b>I70.738</b>	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of other part of lower leg
<b>I70.739</b>	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of unspecified site
<b>I70.74</b>	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration
<b>I70.741</b>	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of thigh
<b>I70.742</b>	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of calf
<b>I70.743</b>	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of ankle
<b>I70.744</b>	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of heel and midfoot
<b>I70.745</b>	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of other part of foot
<b>I70.748</b>	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of other part of lower leg
<b>I70.749</b>	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of unspecified site
<b>I70.75</b>	Atherosclerosis of other type of bypass graft(s) of other extremity with ulceration
<b>I70.76</b>	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene
<b>I70.761</b>	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, right leg
<b>I70.762</b>	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, left leg
<b>I70.763</b>	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, bilateral legs
<b>I70.768</b>	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, other extremity
<b>I70.769</b>	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, unspecified extremity
<b>I70.79</b>	Other atherosclerosis of other type of bypass graft(s) of the extremities
<b>I70.791</b>	Other atherosclerosis of other type of bypass graft(s) of the extremities, right leg
<b>I70.792</b>	Other atherosclerosis of other type of bypass graft(s) of the extremities, left leg
<b>I70.793</b>	Other atherosclerosis of other type of bypass graft(s) of the extremities, bilateral legs
<b>I70.798</b>	Other atherosclerosis of other type of bypass graft(s) of the extremities, other extremity
<b>I70.799</b>	Other atherosclerosis of other type of bypass graft(s) of the extremities, unspecified extremity
<b>I70.8</b>	Atherosclerosis of other arteries
<b>I70.9</b>	Other and unspecified atherosclerosis
<b>I70.91</b>	Generalized atherosclerosis
<b>I70.92</b>	Chronic total occlusion of artery of extremities

**I73: Other peripheral vascular diseases**

<b>I73.8</b>	Other specified peripheral vascular diseases
<b>I73.9</b>	Peripheral vascular disease, unspecified

**Important Safety Information (cont'd)**

In the primary hyperlipidemia trials, liver-related disorders (primarily related to abnormalities in liver enzymes) were reported in 2.5% of patients treated with PRALUENT and 1.8% of patients treated with placebo, leading to treatment discontinuation in 0.4% and 0.2% of patients, respectively.

Increases in serum transaminases to greater than 3 times the upper limit of normal occurred in 1.7% of patients treated with PRALUENT and 1.4% of patients treated with placebo.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.

**Praluent**<sup>®</sup>  
(alirocumab) Injection 75mg/mL  
150mg/mL

**Z83: Family history of other specific disorders**

Z83.42 Family history of familial hypercholesterolemia

**Z95: Presence of cardiac and vascular implants and grafts**

Z95.1 Presence of aortocoronary bypass graft

Z95.5 Presence of coronary angioplasty implant and graft

Z95.820 Peripheral vascular angioplasty status with implants and grafts

**Z98: Other postprocedural states**

Z98.6 Angioplasty status

Z98.61 Coronary angioplasty status

Z98.62 Peripheral vascular angioplasty status

**Need additional support?**Call **1-844-PRALUENT** (1-844-772-5836), Monday–Friday, 8 AM–8 PM Eastern time or visit **PRALUENT.com****Frequently used codes for my office***Use this section to keep track of the ICD-10-CM diagnosis codes that your office uses when prescribing PRALUENT or enrolling patients in MyPRALUENT®.*

ICD-10-CM diagnosis code	Code description
_____	_____
_____	_____
_____	_____
_____	_____
_____	_____
_____	_____
_____	_____

**Important Safety Information (cont'd)**

In the primary hyperlipidemia trials, the most common adverse reactions leading to treatment discontinuation in patients treated with PRALUENT were allergic reactions (0.6% versus 0.2% for PRALUENT and placebo, respectively) and elevated liver enzymes (0.3% versus <0.1%).

PRALUENT is a human monoclonal antibody. As with all therapeutic proteins, there is a potential for immunogenicity with PRALUENT.

**Reference:** 1. 2020 ICD-10-CM. Centers for Medicare & Medicaid Services website. <https://www.cms.gov/Medicare/Coding/ICD10/2020-ICD-10-CM>. Updated January 27, 2020. Accessed March 9, 2020.

Please [click here](#) for full Prescribing Information.

**REGENERON**

©2020 Regeneron Pharmaceuticals, Inc. All rights reserved.  
03/2020 PRA.20.03.0021



**Praluent**<sup>®</sup>  
(alirocumab) Injection 75mg/mL  
150mg/mL